Fujita Hideki, Iwasaki Ryoko, Tsuboi Satoshi, Murashiuma Yoko, Akiyama Masashi
Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan.
J Dermatol. 2024 Mar;51(3):380-390. doi: 10.1111/1346-8138.17089. Epub 2024 Jan 31.
Generalized pustular psoriasis (GPP), a rare form of psoriasis, is characterized by neutrophil-rich, sterile pustules. In Japan, GPP has intractable and rare disease designation, which allows patients to access support from national and local governments for medical expenses. Previously, similar numbers of patients in Tokyo and Hokkaido have been shown to have GPP designation, despite different population sizes. Here, we determine whether there are regional differences in the proportion of patients receiving GPP designation status in Japan and aim to identify causal factors. In this descriptive, retrospective cohort study, publicly available data were collected on the number of patients with intractable and rare disease designation for GPP in each prefecture and age classification (April 2018-March 2021). Three other designated intractable and rare disease cohorts were included: pemphigus, rare skin diseases, and all diseases. The primary outcome was the standardized morbidity ratio (SMR) of patients at prefecture level (observed numbers divided by expected). Regional differences were compared with the statistical expectation for the total population and age distribution of each prefecture. Regional differences were observed in all cohorts. Overall, 1910 patients had GPP as a designated intractable and rare disease in 2020. Regional differences in SMRs for GPP were observed with high SMRs (≥1.5) in Hokkaido, Tottori, Kagawa, and Miyazaki, and low SMRs (<0.6) in Gunma and Kanagawa. Regional differences in SMRs for GPP did not correlate with the number of medical doctors or dermatologists or internal migration. The number of medical doctors or dermatologists correlated with SMRs in the rare skin diseases and total cohorts. Regional differences in Japan exist in the number of patients with GPP who have an intractable and rare disease designation. Managing rare diseases is an important public health issue, and further research is required to elucidate the factors contributing to these differences.
泛发性脓疱型银屑病(GPP)是一种罕见的银屑病形式,其特征为富含中性粒细胞的无菌脓疱。在日本,GPP被认定为难治性罕见病,这使得患者能够获得国家和地方政府在医疗费用方面的支持。此前研究表明,尽管东京和北海道人口规模不同,但两地区具有GPP认定的患者数量相近。在此,我们确定日本接受GPP认定状态的患者比例是否存在地区差异,并旨在找出相关因果因素。在这项描述性回顾性队列研究中,我们收集了各都道府县GPP难治性罕见病认定患者数量及年龄分类的公开数据(2018年4月至2021年3月)。另外还纳入了其他三个指定的难治性罕见病队列:天疱疮、罕见皮肤病和所有疾病。主要结局指标是各都道府县患者的标准化发病比(SMR,观察病例数除以预期病例数)。将地区差异与各都道府县总人口和年龄分布的统计预期进行比较。在所有队列中均观察到了地区差异。总体而言,2020年有1910名患者的GPP被认定为难治性罕见病。GPP的SMR存在地区差异,北海道、鸟取县、香川县和宫崎县的SMR较高(≥1.5),而群马县和神奈川县的SMR较低(<0.6)。GPP的SMR地区差异与医生或皮肤科医生数量或内部迁移无关。医生或皮肤科医生数量与罕见皮肤病队列和所有疾病队列的SMR相关。日本GPP难治性罕见病认定患者数量存在地区差异。管理罕见病是一个重要的公共卫生问题,需要进一步研究以阐明导致这些差异的因素。